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Innate immune defense against pathogens in-
volves interactions between conserved micro-
bial molecular motifs and pattern recognition 
receptors (PRRs; Janeway and Medzhitov, 2002), 
such as the Toll-like receptors (TLRs; Ishii   
et al., 2008) and C-type lectins (Gordon, 2002; 
Geijtenbeek  et  al.,  2004;  Robinson  et  al., 
2006), expressed on host phagocytic cells. The 
binding of microbial ligands to PRR results in 
various immune effector functions, including 
phagocytosis, oxidative burst (Saijo et al., 2007; 
Taylor et al., 2007), secretion of antimicrobial 
peptides (Liu et al., 2006), autophagy (Delgado 
et al., 2008), and the production of inflamma-
tory cytokines, which help the body to resist 
pathogens either directly or by shaping the 
adaptive immune response (Medzhitov, 2007). 
Conversely, inappropriate innate responses, 
caused by mutations in PRR-encoding genes, 
for example, may lead to pathogen persistence 
and profound effects on host susceptibility to 
infection (Quintana-Murci et al., 2007).
C-type lectins constitute an extensive fam-
ily of receptors involved in the recognition of 
endogenous and microbial carbohydrates in a 
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The C-type lectin dendritic cell−specific intercellular adhesion molecule-3 grabbing nonin-
tegrin (DC-SIGN) mediates the innate immune recognition of microbial carbohydrates. We 
investigated the function of this molecule in the host response to pathogens in vivo, by 
generating mouse lines lacking the DC-SIGN homologues SIGNR1, SIGNR3, and SIGNR5. 
Resistance to Mycobacterium tuberculosis was impaired only in SIGNR3-deficient animals. 
SIGNR3 was expressed in lung phagocytes during infection, and interacted with M. tuber-
culosis bacilli and mycobacterial surface glycoconjugates to induce secretion of critical host 
defense inflammatory cytokines, including tumor necrosis factor (TNF). SIGNR3 signaling 
was dependent on an intracellular tyrosine-based motif and the tyrosine kinase Syk. Thus, 
the mouse DC-SIGN homologue SIGNR3 makes a unique contribution to protection of the 
host against a pulmonary bacterial pathogen.
© 2009 Tanne et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e2206 ROLE OF DC-SIGN IN TUBERCULOSIS | Tanne et al.
et al., 2006). SIGNR1 binds terminal mannose motifs in my-
cobacterial ManLAM (Koppel et al., 2004), but SIGNR1-
deficient mice have no phenotype upon M. tuberculosis infection 
(Wieland et al., 2007). SIGNR3 is the only one of the seven 
mouse homologues that, like human DC-SIGN, shows dual 
specificity for both glycans with high mannose content and fu-
cose-containing oligosaccharides, including the LewisX antigen 
(Powlesland et al., 2006). Furthermore, like human DC-SIGN, 
SIGNR3 forms tetramers, mediates endocytosis, and releases 
bound ligands in acidic conditions (Powlesland et al., 2006). 
Collectively, these data suggest that SIGNR3 is the best candi-
date for a functional orthologue of human DC-SIGN.
We investigated the role of members of the DC-SIGN 
family in TB in vivo in more detail by generating mice lack-
ing three homologues of human DC-SIGN, namely SIGNR1 
and SIGNR3, the homologues that are biochemically most 
similar to human DC-SIGN, and the more divergent SIGNR5. 
KO animals were generated directly in a C57BL/6 genetic 
background so that backcrosses were not required for back-
ground purification. We assessed the susceptibility of these 
mice to M. tuberculosis and compared the results obtained 
with those for WT animals. We report that only SIGNR3-
deficient mice have impaired pulmonary defenses against the 
bacillus, whereas SIGNR1- and SIGNR5-deficient animals 
show no particular phenotype upon infection. Consistent 
with this finding, we report that, like human DC-SIGN in 
patients with TB (Tailleux et al., 2005), SIGNR3 is expressed 
in lung (myeloid) cells during the course of M. tuberculosis   
infection, whereas it is not expressed in naive animals. Myco-
bacterial recognition by SIGNR3 induces a signaling cascade 
requiring the tyrosine kinase Syk and involving a YxxI motif 
in the cytoplasmic tail of SIGNR3. This motif resembles the 
immunoreceptor  tyrosine–based  activation  motif  (ITAM)-
like YxxI/L found in other C-type lectins, such as dectin-1 
(Brown,  2006).  SIGNR3  signaling  activates  macrophages, 
inducing the production of inflammatory cytokines, includ-
ing TNF, in an NF-B– and Raf1–ERK-dependent path-
way, with these cytokines being key components of protec 
tion against TB (Flynn et al., 1995; Ladel et al., 1997; Saunders 
et al., 2000).
RESULTS
SIGNR1 and SIGNR3 recognize M. tuberculosis  
and mycobacterial surface glycoconjugates
We evaluated the capacity of the murine DC-SIGN homo-
logues to recognize mycobacterial ligands, by carrying out 
binding experiments with 125I-labeled recombinant SIGNR 
proteins incubated with various mycobacterial lipoglycans, 
including M. tuberculosis–derived ManLAM and lipomannan 
(LM), Mycobacterium chelonae–derived LAM (AraLAM; Fig. 1 a), 
and the M. tuberculosis–derived 19-, 38-, and 45-kD glyco-
proteins. These molecules were used to coat plastic plates. 
Like human DC-SIGN, SIGNR3 recognized ManLAM and 
LM, but did not bind to AraLAM, which has no mannose-
capping residues. However, to a lesser extent, SIGNR3, like 
human DC-SIGN, also recognized mycobacterial glycoproteins, 
calcium-dependent manner (Weis et al., 1998). DC-specific 
intercellular adhesion molecule-3 grabbing nonintegrin (DC-
SIGN) is a prototypic member of the C-type lectin family 
(Geijtenbeek et al., 2000). This molecule facilitates broad   
immune surveillance by DCs and some subsets of macrophages, 
through interactions with fucose- and mannose-containing 
glycans on many viruses, bacteria, and parasites (Robinson   
et al., 2006). In particular, DC-SIGN is an important recep-
tor for M. tuberculosis, the pulmonary bacterial pathogen re-
sponsible  for  tuberculosis  (TB;  Geijtenbeek  et  al.,  2003; 
Tailleux et al., 2003, 2005; Torrelles et al., 2008). DC-SIGN 
recognizes mannose residues in glycoproteins and lipogly-
cans, such as mannosylated lipoarabinomannan (ManLAM), 
in the mycobacterial cell envelope (Geijtenbeek et al., 2003; 
Maeda et al., 2003; Tailleux et al., 2003; Pitarque et al., 2005). 
A transgenic knockin model of “humanized” mice express-
ing DC-SIGN (Schaefer et al., 2008) has suggested that this 
lectin may be involved in protection against TB pathogenesis. 
Other in vitro studies have suggested that DC-SIGN may be 
exploited by M. tuberculosis as a means of evading immune 
surveillance and persisting in the host (Geijtenbeek et al., 
2003). Genetic association studies in TB patients and healthy 
contacts have led to conflicting results on whether DC-SIGN 
promotes protection or increases susceptibility to TB (Barreiro 
et al., 2006; Vannberg et al., 2008); nevertheless, both studies 
clearly suggested a role for DC-SIGN in the course of the 
disease. This role remains unclear, particularly because of the 
lack of an appropriate animal model.
The mouse DC-SIGN locus (Park et al., 2001; Powlesland 
et al., 2006) encompasses seven genes, Signr1-5 (also called 
Cd209b, Cd209c, Cd209d, Cd209e, and Cd209a) and Signr7-8 
(also called Cd209g and Cd209f), and one pseudogene, Signr6, 
which is also called Cd209h (Fig. S1). SIGNR5 (also termed 
mDC-SIGN or CIRE) was initially described as the mouse 
orthologue of human DC-SIGN (Park et al., 2001). However, 
further analyses clearly showed that SIGNR5 differs function-
ally from human DC-SIGN (Caminschi et al., 2006; Gramberg 
et al., 2006; Powlesland et al., 2006). Amino acid sequence 
comparison and reconstruction of the phylogeny of these lec-
tins revealed that mouse SIGNR1, SIGNR3, and SIGNR4 
were the homologues most closely related to human DC-
SIGN (Fig. S1). In human DC-SIGN, Val351 is instrumental in 
sugar recognition, particularly in binding fucose residues (Guo 
et al., 2004). The only mouse homologues containing this resi-
due are SIGNR3 and SIGNR4. However, SIGNR4 is unable 
to bind sugars in vitro, probably because the critical calcium-
binding amino acids, Glu347 and Glu354, which are present in all 
other related molecules, have been replaced by Gln residues 
(Powlesland et al., 2006). SIGNR1 does not contain Val351, 
and is thus different from human DC-SIGN, as confirmed by 
the  sugar  recognition  profiles  of  the  two  lectins.  Mouse 
SIGNR1, like human DC-SIGN, recognizes mannose resi-
dues (Geijtenbeek et al., 2002), but it recognizes these residues 
as terminal monosaccharides rather than branched glycans, a 
property common to other C-type lectins outside the DC-
SIGN family, such as the mannose-binding lectin (Powlesland JEM VOL. 206, September 28, 2009 
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fected SIGNR3-expressing and control macrophages of the 
RAW 264.7 line. Cells expressing SIGNR3 displayed mark-
edly higher levels of mycobacterial recognition than control 
cells (Fig. 2 a). Furthermore, macrophages expressing low 
levels of SIGNR3 bound fewer bacteria than macrophages 
expressing higher levels of this lectin in a mixed cell infection 
assay (Fig. 2 b). Our results provide evidence for the recogni-
tion by the DC-SIGN homologue SIGNR3 of M. tuberculosis 
and mycobacterial surface glycoconjugates.
SIGNR1-, SIGNR3-, and SIGNR5-deficient  
mice develop normally
With the aim of evaluating the importance of the DC-SIGN 
homologues SIGNR1, SIGNR3, and SIGNR5 for the con-
trol of M. tuberculosis infection in vivo, we generated three 
including the 19-kD antigen (Fig. 1 b). In contrast, recombi-
nant SIGNR5 bound only weakly to these ligands, and this 
lectin was unable to recognize ManLAM in particular (Fig. 1 
b). As previously reported (Koppel et al., 2004), SIGNR1 
also bound to ManLAM and bound poorly to AraLAM. We 
also found that SIGNR1 recognized several other mycobac-
terial glycoproteins (Fig. 1 b). Thus, SIGNR3 and SIGNR1, 
but not SIGNR5, can interact with mannose-containing my-
cobacterial surface molecules. In addition to binding, the ex-
pression of SIGNR3 and SIGNR1, but not of SIGNR5, 
in  Rat6  fibroblasts  conferred  on  these  cells  an   
ability to mediate endocytosis and to take up ManLAM   
(Fig. 1 c). SIGNR1 has been reported to interact directly 
with M. tuberculosis (Taylor et al., 2004). We wished to evalu-
ate whether this was also true for SIGNR3, therefore  we in-
Figure 1.  SIGNR1 and SIGNR3 bind mycobacterial ligands, whereas SIGNR5 does not. (a) Schematic representation of the mycobacterial lipogly-
cans studied. ManLAM, nonmannosylated lipoarabinomannan (AraLAM), and LM, which were used in the study. MPI, myo-phosphatidylinositol. n, p, q, 
and r indicate variable numbers of motif repeats. (b) 125I-labeled recombinant SIGNR3, SIGNR5, and SIGNR1 were incubated with plastic-associated  
mycobacterial lipoglycans (ManLAM, AraLAM, and LM) or glycoproteins (19, 38, and 45-kD) for 2 h at room temperature. The plastic plates were then 
thoroughly washed and the radioactivity was counted. For comparisons, the fractions of the input radioactivity bound to the plates were calculated from 
the linear portions of the binding curves. Data are mean (± SD) of triplicate samples and were reproduced in two independent experiments. (c) Rat6 fibro-
blasts stably transfected with vectors encoding SIGNR3, SIGNR5, or SIGNR1. Cells were incubated with biotinylated ManLAM for 1 h at 37°C, washed, and 
permeabilized, and ManLAM was detected with Texas red–conjugated streptavidin. Data are representative of three independent experiments. Bar, 10 µm.2208 ROLE OF DC-SIGN IN TUBERCULOSIS | Tanne et al.
phenotype after infection, as shown by comparison with the 
WT. In contrast, SIGNR3-deficient animals had 5–31 times 
more bacteria in their lungs 21 d after infection (14.1 ± 1.9 × 
107 vs. 2.4 ± 0.6 × 107; n = 7; P = 0.0007), and 3–12 times 
more bacteria in their lungs 42 d after infection (0.5 ± 0.107  
vs. 0.1 ± 0.03 × 107, n = 6, P = 0.0095) than did the WT controls   
(Fig. 3 c). No differences were observed in bacterial coloniza-
tion of the spleen, with SIGNR3-deficient animals display-
ing similar levels of colonization to controls (2.4 ± 0.4 × 105  
for both genotypes at day 21; P = 0.9; 0.4 ± 0.105 vs. 0.3 
± 0.03 × 105 on day 42; P = 0.4; Fig. 3 c). These results 
were reproduced in two independent experiments and in-
dicated a role for SIGNR3 in early pulmonary resistance to 
M. tuberculosis, but not in mycobacterial dissemination or the 
extrapulmonary control of infection in secondary lymphoid 
organs. Although the difference in lung CFUs between WT 
and SIGNR3-deficient animals persisted in the longer term 
(after 21 d), infection was controlled in KO mice, as attested 
by the observed decrease in pulmonary bacterial load. These 
results suggest that SIGNR3 is involved in the early control   
of M. tuberculosis infection but does not play a major role in 
mounting  an  efficient  antimycobacterial  adaptive  immune 
response.  Consistent  with  this  hypothesis,  we  observed 
no difference in the formation of granulomatous lesions 
in SIGNR3-deficient and SIGNR3-containing mice, in 
recombinant KO mouse lines carrying deletions of exons 1–4 
of Signr1 (Fig. S2 a), and of exons 1–5 of Signr3 (Fig. S3 a) 
and Signr5 (Fig. S4 a) in the C57BL/6 background, to over-
come the need for backcrosses for the purification of genetic 
background. Genotyping by PCR and Southern blotting (not 
depicted) together with RT-PCR analysis confirmed that 
the Signr1 (Fig. S2 b), Signr3 (Fig. S3 b), and Signr5 (Fig. S4 b) 
transcripts were not produced in animals with the corre-
sponding inactivations. The expected Mendelian ratio of KO 
mice was obtained, and these animals were fertile. Detailed 
histological,  hematological,  immunological,  and  metabolic 
analyses were performed on KO animals and are continuing. 
Data are available at the Consortium for Functional Glycom-
ics Gateway (http://www.functionalglycomics.org/glycomics/
publicdata/phenotyping.jsp).
SIGNR3 is involved in early host resistance  
to M. tuberculosis
We evaluated the impact of an absence of DC-SIGN homo-
logues on resistance to mycobacteria, by infecting KO mice 
and their WT C57BL/6 counterparts intranasally with 1,000 
M. tuberculosis CFUs. We recovered lungs and spleens from 
animals on days 1, 21, and 42 after infection and determined 
their CFU content. Mice lacking SIGNR1 (Fig. 3 a) and 
SIGNR5 (Fig. 3 b) displayed no particular lung or spleen 
Figure 2.  SIGNR3 recognizes M. tuberculosis bacilli. (a) RAW and RAW-SIGNR3 cells were analyzed by flow cytometry for SIGNR3 expression (left ). 
Both cell types were infected with M. tuberculosis H37Rv expressing RFP at a multiplicity of infection of 5 bacteria per cell, for 4 h at 37°C; cells were 
then washed, fixed, and analyzed for M. tuberculosis content by flow cytometry. (b) A heterogeneous SIGNR3-expressing RAW cell line was analyzed by 
flow cytometry for SIGNR3 expression. SIGNR3lo and SIGNR3+ cells were observed. The cells were infected as in a and further stained with an anti-
SIGNR3 antibody that was subsequently detected with an Alexa Fluor 647–conjugated secondary antibody. Mycobacterial content was analyzed by flow 
cytometry after gating on SIGNR3lo and SIGNR3hi cells. In a and b, the percentages indicate M. tuberculosis–positive cells. Experiments were repeated 
twice and representative panels are shown.JEM VOL. 206, September 28, 2009 
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immunodetected  in  lung  tissues  of  M.  tuberculosis-infected 
mice, but not in those of naive animals or of M. tuberculosis–
infected  SIGNR3-deficient  mice  (Fig.  5  a).  Interestingly, 
high- (Fig. 4 a) and low-dose infection models (not depicted). 
Furthermore, SIGNR3-KO animals mounted specific anti-
mycobacterial Th1, Th2, Tc1, and Th17 responses similar in 
strength and kinetics to those of WT controls (Fig. 4 b). Finally, 
SIGNR3-KO mice did not die any earlier than WT controls in 
two independent experiments with the laboratory strain H37Rv 
and a more virulent strain of the W-Beijing lineage, over infec-
tion periods of 170 and 190 d (unpublished data).
SIGNR3 is expressed in the lungs of M. tuberculosis–
infected mice
In humans infected with M. tuberculosis, DC-SIGN is ex-
pressed in lung phagocytes, including alveolar macrophages 
(Tailleux et al., 2005). We investigated whether SIGNR3 
displays a similar pattern of expression in mice. SIGNR3 was 
Figure 3.  SIGNR3-deficient mice are less resistant to M. tuber-
culosis infection than WT mice. (a–c) SIGNR1- (a), SIGNR5- (b), and 
SIGNR3-deficient (c) mice (open circles) and their WT counterparts (closed   
circles) were infected intranasally with 1,000 CFUs of M. tuberculosis 
H37Rv. On days 1, 21, and 42 after infection lungs (left) and spleens 
(right) were collected from the animals, homogenized, and plated on agar 
medium for CFU counting. Each circle represents one animal. Data are 
representative of at least two independent experiments. When not indi-
cated, P > 0.05. p.i., postinfection; ns, not significant.
Figure 4.  The antimycobacterial adaptive immune response is in-
tact in SIGNR3-deficient mice. (a) Typical pulmonary granulomas ob-
served 21 d after intranasal infection with 1,000 CFU M. tuberculosis 
H37Rv/mouse, from C57BL/6 (left) and SIGNR3-deficient (right) mice. 
Sections were stained with hematoxylin and eosin. Bars, 150 µm. (b) WT 
and SIGNR3-KO mice were infected as in a. Lungs were recovered 21 d 
after infection, and total lung cells were restimulated with purified pro-
tein derivative for 6 h. Intracellular IFN-, IL-4, and IL-17 and surface CD4 
and CD8 staining made it possible to identify pulmonary Th1, Th2, Tc1, 
and Th17 cells. The data shown are the means (± SD) of quadruplicate 
samples/mice, reproduced in two independent experiments. As on day 21, 
no differences between SIGNR3-KO mice and WT controls were observed 
15 and 42 d after infection (not depicted).2210 ROLE OF DC-SIGN IN TUBERCULOSIS | Tanne et al.
within  the  cellular  infiltrates,  part  of  SIGNR3-expressing 
cells displayed typical morphological features of multinucle-
ated giant cells (Fig. 5 b, top); other SIGNR3-expressing 
cells were located in the alveoli and resembled alveolar mac-
rophages (Fig. 5 b, bottom). Double immunostaining experi-
ments were used to characterize SIGNR3-expressing cells in 
the cellular infiltrate; SIGNR3-positive cells expressed no or 
low levels of MHC-II and CD11c, and some of them ex-
pressed  NOS2/iNOS  and  the  macrophage  marker  F4/80 
(Fig. 5 c). These observations parallel the reported pattern of 
DC-SIGN expression in the lungs of patients with TB, with   
SIGNR3+  cells  in  the  lungs  of  infected  animals  being  of   
myeloid origin (Tailleux et al., 2005).
SIGNR3 binding to ManLAM and M. tuberculosis induces 
the secretion of IL-6 and TNF
Lung inflammatory cytokines play a crucial role in host resis-
tance to M. tuberculosis (Flynn and Chan, 2001). We investigated 
whether SIGNR3 stimulation induced cytokine secretion, by 
stably transfecting RAW 264.7 macrophages with a SIGNR3-
encoding vector, and stimulating them with ManLAM for vari-
ous periods of time. We then quantified cytokine levels in culture   
supernatants  by  ELISA.  ManLAM  stimulation  of  SIGNR3-
  expressing cells resulted in the strong induction of IL-6 secretion, 
as shown by comparison with control cells (Fig. 6 a). Larger 
amounts of TNF were also produced by SIGNR3-expressing 
macrophages than by control cells (Fig. 6 b). IL-1 and IL-12p40 
were not detected in any conditions in stimulated RAW and 
RAW-SIGNR3 cells (unpublished data). Nitric oxide, an im-
portant mediator of resistance to M. tuberculosis in mice and pos-
sibly also in humans (Flynn and Chan, 2001), was not produced 
in larger amounts in SIGNR3-expressing macrophages than in 
control cells after stimulation with ManLAM (Fig. S5 a). IL-10 
was barely induced in ManLAM-treated macrophages, regardless 
of SIGNR3 expression, and ManLAM did not potentiate IL-10 
secretion in LPS-treated SIGNR3-expressing cells (Fig. S5 b). 
Infection with live M. tuberculosis also resulted in higher levels of 
production of IL-6 (Fig. 6 c) and TNF (Fig. 6 d) in SIGNR3-
expressing cells than in control cells. We wanted to use BM-
  derived  phagocytic  cells  from  SIGNR3-deficient  animals  to 
confirm these results in a primary context. However, flow cy-
tometry analysis of the macrophages and DCs derived from BM 
progenitors of WT mice using various classical cytokines, such as 
M-CSF, GM-CSF, and Flt3-ligand, resulted in no detection of 
SIGNR3 mRNA or protein in these cells (unpublished data). 
The treatment of these cells with cytokines, such as IL-4 and IL-
13, which are known to induce DC-SIGN expression in human 
phagocytes (Soilleux et al., 2002; Puig-Kröger et al., 2004), also 
failed to increase SIGNR3 expression (unpublished data). We 
could not purify SIGNR3-expressing cells from the lungs of   
M. tuberculosis–infected animals in a sufficiently pure state and in 
Figure 5.  SIGNR3 is expressed in the lungs during M. tuberculosis 
infection. (a) Lung sections from uninfected (left) and M. tuberculosis–
infected (right) WT (top right) and SIGNR3-KO mice (bottom right) were 
stained with the nuclear staining agent TO-PRO-3 (blue) and with a rabbit 
polyclonal anti-SIGNR3 IgG fraction that was subsequently detected with 
a Cy3-coupled anti–rabbit antibody (red). The images in the right columns 
are magnified from the white boxes in the middle column. Faint red sig-
nals in all panels (illustrated in the circle in the top left image) correspond 
to autofluorescent erythrocytes (el-Rahman et al., 1995). (b) Lung sections 
from M. tuberculosis–infected WT mice were stained for SIGNR3 as in a. 
Arrowheads in left image indicate multinucleated giantlike cells; arrow-
heads in right image indicate alveolar macrophage-like cells in the alveoli. 
(c) Lung sections from M. tuberculosis–infected WT mice were stained for 
SIGNR3 as in a, and then counterstained (green; Alexa Fluor 488) for 
MHC-II, CD11c, NOS2, and F4/80, as indicated. Arrowheads indicate colo-
calization. Pictures are representative of at least two independent experi-
ments using samples collected from different animals. Bars, 50 µm.
 JEM VOL. 206, September 28, 2009 
ARTICLE
2211
large enough quantities. We therefore decided to validate the 
functionality of SIGNR3 signaling in primary cells by nucleo-
fecting BM-derived macrophages (BMMs) with a SIGNR3-
encoding vector. SIGNR3 expression in BMMs was validated 
by RT-PCR (unpublished data). The treatment of these cells 
with ManLAM again resulted in much higher levels of IL-6 
(Fig. 6 e) and TNF (Fig. 6 f) secretion than observed in BMMs 
transformed with a control vector. IL-6 and TNF play key roles 
in antimycobacterial immunity, and IL-6– and TNF-deficient 
mice are particularly susceptible to mycobacteria (Flynn et al., 
1995; Ladel et al., 1997; Saunders et al., 2000). We quantified 
IL-6 and TNF production in the lungs of WT and SIGNR3-
deficient animals. On day 21 after infection, the level of TNF 
was significantly lower in KO than in WT mice (Fig. 6 g). 
The level of IL-6 was also lower in the lungs of KO animals, al-
though the difference with that in the lungs of WT controls did 
not reach statistical significance (Fig. 6 h).
SIGNR3 signaling is dependent on Tyr27 and does not 
require TLR2
We next investigated the molecular bases of SIGNR3-mediated 
signaling and IL-6 and TNF production. Although ManLAM is 
a poor ligand for TLR2 (Nigou et al., 2008), we investigated the 
possible involvement of TLR2 in SIGNR3-dependent IL-6 and 
TNF secretion after ManLAM recognition, and the possibility 
that SIGNR3 signals on its own. Neutralizing anti-TLR2   
antibodies did not inhibit the cytokine secretion induced by 
SIGNR3 stimulation with ManLAM, although the antibody 
was clearly active in cells stimulated with the TLR2 ligand lipo-
peptide Pam3Cys-SK4 (Fig. 7 a). The cytoplasmic tail of SIGNR3 
contains a tyrosine residue (Y27) in the vicinity of an ITAM-like 
motif (Fig. 7 b). As in other C-type lectins, such as dectin-1/
CLEC-7A and CLEC-2, this residue may be involved in signal 
transduction. We thus transfected macrophages with a vector 
encoding a Y27S mutant form of SIGNR3. Like WT SIGNR3, 
the mutated form of the receptor was correctly immunodetected 
in the cytoplasm and at the plasma membrane of transfected cells 
(Fig. 7 c), and the two forms were expressed at similar levels   
(Fig. 7 d). The Y27S mutation strongly impaired SIGNR3 signal 
transduction and the induction of IL-6 and TNF (Fig. 7 e) secre-
tion after stimulation with ManLAM. The secretion of IL-6 and 
TNF was also weaker in M. tuberculosis–infected macrophages 
expressing the mutated form of SIGNR3 than in cells expressing 
the WT lectin (Fig. 7 f). As a control, macrophages expressing 
the WT or the mutated form of SIGNR3 responded similarly to 
non-SIGNR3  ligands,  such  as  FSL-1  (TLR2/6  ligand)  and 
Pam3CSK4 (TLR1/2 ligand), as shown by IL-6 and TNF pro-
duction (Fig. 7 g).
SIGNR3 signaling depends on the tyrosine kinase Syk  
and the Raf1–ERK and NF-B pathways
We investigated the impact of SIGNR3 on the secretion of 
IL-6 and TNF using chemical inhibitors to target various 
steps in the regulation of intracellular transduction pathways. 
We showed that SIGNR3 signaling was dependent on both 
the NF-B and the Raf1–ERK pathways (Fig. 8, a and b). 
Figure 6.  SIGNR3 binding to ManLAM and M. tuberculosis induces 
the secretion of IL-6 and TNF. (a) RAW 264.7–derived macrophages 
stably transfected with a SIGNR3-encoding (circles) or an empty control 
(squares) vector were left unstimulated (open symbols) or were stimulated 
(closed symbols) with 10 µg/ml ManLAM, and IL-6 secretion was mea-
sured by ELISA after 4, 12, and 24 h of incubation. (b) TNF secretion by 
RAW-derived macrophages. The same protocol described for a was fol-
lowed. (c and d) RAW (open bars) and RAW-SIGNR3 (filled bars) cells were 
infected with M. tuberculosis H37Rv (10 bacteria/cell) or left untreated 
(NS, nonstimulated) for 4 h; cells were washed and further incubated in 
bacterium-free medium for 14 h, and IL-6 (c) and TNF (d) were measured 
by ELISA. (e and f) BMMs from C57BL/6 mice were nucleofected with a 
control vector (Ctrl) or with a SIGNR3-encoding vector and were stimu-
lated with 10 µg/ml ManLAM (+) or left untreated (); IL-6 (e) and TNF  
(f) levels were determined by ELISA after 18 h of incubation. (g and h) WT 
(filled bars) and SIGNR3-KO mice (open bars) were infected intranasally 
with 1,000 CFUs M. tuberculosis H37Rv, and lungs were analyzed for TNF 
(g) and IL-6 (h) after 21 d of infection. In a–f, the data shown are the 
means (± SD) of triplicate samples, reproduced in at least two indepen-
dent experiments. In g and h, the data shown are the means (± SD) of 
quadruplicate samples/mouse, reproduced in two independent experi-
ments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.2212 ROLE OF DC-SIGN IN TUBERCULOSIS | Tanne et al.
Figure 7.  SIGNR3 signaling is TLR2-independent and involves intracellular Tyr27. (a) SIGNR3-expressing RAW 264.7 macrophages were left un-
stimulated (dashed bars) or were stimulated with 10 µg/ml ManLAM or 0.5 µg/ml lipopeptide Pam3-CysSK4 in the absence (black bars) or presence of anti-
TLR2 antibody (gray bars) or the corresponding isotype control (white bars). After 18 h of incubation, the secretion of IL-6 and TNF (as indicated) was 
measured by ELISA. Data represent cytokine production as a mean percentage (± SD) of production by cells stimulated in the absence of antibody (black JEM VOL. 206, September 28, 2009 
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inflammatory cytokine secretion after the recognition of   
mycobacterial agonists.
DISCUSSION
This study provides evidence that the functional DC-SIGN 
homologue SIGNR3 contributes to early host resistance to 
M. tuberculosis in experimentally infected mice, and that Syk-
coupled SIGNR3 signaling triggers secretion of the protec-
tive inflammatory cytokines IL-6 and TNF in a NF-B and 
Raf1–ERK–dependent manner. SIGNR3 signaling is trig-
gered  by  ManLAM,  which  is  only  a  weak  TLR2  ligand 
(Means et al., 1999; Nigou et al., 2008), as well as by LM, a 
strong TLR2 ligand (Nigou et al., 2008). SIGNR3 activation 
is entirely dependent on an ITAM-like motif in the cytoplas-
mic tail of the lectin, and is not altered by anti-TLR2 neu-
tralizing  antibodies.  In  addition  to  signaling  on  its  own, 
SIGNR3 may act with TLR2, in an additive manner, to in-
crease cytokine secretion after recognition of dual ligands 
such as the 19-kD protein.
The mouse DC-SIGN locus differs from its human ho-
mologue in several ways. In particular, it has been intensely 
remodeled  through  gene  duplication,  generating  seven   
paralogous genes and one pseudogene, whereas the human   
DC-SIGN gene is flanked by only one paralogue, L-SIGN. Se-
quence analysis and phylogeny reconstruction alone could 
not identify the true mouse orthologue of human DC-SIGN 
(Powlesland  et  al.,  2006).  However,  biochemical  studies 
clearly demonstrated that only SIGNR3 displayed dual speci-
ficity for mannose- and fucose-containing oligosaccharides 
and glycans, like human DC-SIGN. It is therefore not sur-
prising that, like DC-SIGN, SIGNR3 binds to and internal-
izes M. tuberculosis ManLAM through its mannose capping 
residues. We also showed that SIGNR3 bound other myco-
bacterial lipoglycans, such as LM, and glycoproteins, such as 
the 19-kD antigen, and whole M. tuberculosis bacilli. SIGNR1 
also recognizes M. tuberculosis ManLAM, as previously re-
ported (Koppel et al., 2004), in addition to mycobacterial 
glycoproteins. However, the properties of SIGNR1 are not 
consistent with strong functional similarities to human DC-
SIGN.  Indeed,  SIGNR1  recognizes  terminal  monosac-
charides  rather  than  mannose-branched  oligosaccharides 
(Powlesland et al., 2006). Moreover, SIGNR1 is expressed in 
ERK activation after signal transduction by a C-type lectin 
was  reminiscent  of  recent  findings  for  the  Syk-coupled   
C-type lectin dectin-1 (Rogers et al., 2005). Specific inhibition 
of the tyrosine kinase Syk by piceatannol abolished SIGNR3 
signaling and cytokine secretion in a dose-dependent manner 
(Fig. 8 c). In contrast, this Syk inhibitor had no effect on 
TLR2-induced cytokine production (Fig. 8 c). The more 
specific Syk inhibitor R406 gave similar results (Fig. 8 d).   
Finally, SIGNR3 trans-expression in BMMs from Syk-defi-
cient mice (Turner et al., 1995) resulted in much lower levels 
of IL-6 production upon ManLAM treatment than were ob-
served for BMMs with active Syk (Fig. 8 e). Thus, the recog-
nition of mycobacterial sugar motifs by the C-type lectin 
SIGNR3 induces TLR2-independent, Syk-dependent secre-
tion of the proinflammatory cytokines IL-6 and TNF.
SIGNR3 collaborates with TLR2 to induce  
inflammatory cytokines
SIGNR3 signaling after ManLAM recognition was TLR2-
independent. However, mycobacteria express TLR2 ligands, 
some of which, including the 19-kD antigen (Brightbill   
et al., 1999), are also recognized by C-type lectins (Pitarque 
et al., 2005). We therefore decided to evaluate the effect of 
SIGNR3 in the context of macrophage stimulation by my-
cobacterial TLR2 ligands such as the 19-kD antigen. The 
19-kD protein is recognized by SIGNR3 (Fig. 1 b), and 
SIGNR3 allows nonphagocytic cells to take up the antigen 
by endocytosis (Fig. 9 a). SIGNR3 expression in RAW mac-
rophages clearly increased the secretion of IL-6 and TNF 
(Fig. 9 b) after stimulation with the 19-kD protein, as shown 
by comparison with control cells. The blocking of TLR2 
with an antibody reduced cytokine secretion in SIGNR3+ 
cells after 18 h of stimulation (Fig. 9 c), confirming that 
TLR2 was required for 19-kD protein–induced signaling. 
Finally, IL-6 secretion was partially impaired in Syk-deficient 
BMMs trans-expressing SIGNR3 and stimulated with the 
19-kD antigen (Fig. 9 d). The LAM and LM contents of the 
19-kD  lipoprotein  fraction  were  assessed  by  carbohydrate 
quantification based on capillary electrophoresis (Nigou   
et al., 2000), after total acid hydrolysis, and were found to be 
<3% (unpublished data). Thus, in addition to signaling on its 
own, SIGNR3 can “collaborate” with TLR2 to induce pro-
bars, 100%). 100% of IL-6 secretion after stimulation with ManLAM and lipopeptide corresponded to 9.5 ± 1.8 and 5.4 ± 0.5 ng/ml, respectively. 100% of 
TNF secretion after stimulation with ManLAM and lipopeptide corresponded to 8.4 ± 0.2 and 9.4 ± 0.2 ng/ml, respectively. (b) Amino acid sequence align-
ment of the ITAM-like signaling motif (YXXL/I) in CLEC-2, dectin-1/CLEC-7A, FcRII, hDC-SIGN, and the corresponding sequence in SIGNR3 and in a Y27S-
mutated form of SIGNR3. The critical tyrosine residue is shown in red; the second typical residue is shown in green, the ITAM-like motif is indicated by a 
boxed area. (c and d) SIGNR3- and SIGNR3(Y27S)-expressing RAW 264.7 macrophages were stained with a rat anti-SIGNR3 antibody, which was subse-
quently detected with an Alexa Fluor 594– (c) or an Alexa Fluor 647–conjugated (d) anti–rat monoclonal antibody, and were analyzed by confocal micros-
copy (c) or by flow cytometry (d). Data are representative of two independent experiments. Bar: (c) 10 µm. (e) RAW 264.7 macrophages expressing SIGNR3 
(gray bars) and SIGNR3(Y27S) (white bars) were left unstimulated (NS) or were stimulated with 10 µg/ml ManLAM. After 18 h of incubation, the secretion 
of IL-6 (left) and TNF (right) was assessed by ELISA. (f) RAW 264.7 macrophages expressing SIGNR3 (gray bars) and SIGNR3(Y27S) (open bars) were in-
fected with M. tuberculosis H37Rv (10 bacteria/cell). Cells were treated as in Fig. 6 (c and d), and IL-6 (left) and TNF (right) levels were determined by 
ELISA. (g) RAW 264.7 macrophages expressing SIGNR3 (dark gray bars) and SIGNR3(Y27S) (light gray bars) were stimulated with 0.5 µg/ml Pam3CSK4 or  
0.1 µg/ml FSL-1 (Pam2CGDPKHPKSF). After 18 h of incubation, the secretion of IL-6 (left) and TNF (right) was assessed by ELISA. In a and e–g, the data 
shown are the means (± SD) of triplicate samples, reproduced in at least two independent experiments. *, P < 0.05; **, P < 0.01.
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Figure 8.  SIGNR3 signaling involves Syk and Raf1. (a) SIGNR3-expressing RAW 264.7 macrophages were stimulated with 10 µg/ml ManLAM in the 
absence (dashed bars) or presence of the 10 µM ERK1/2 kinase inhibitor U0126 (dark gray bars) or 10 µM I-B kinase inhibitor BAY117082 (light gray 
bars). After 18 h of incubation, the secretion of IL-6 and TNF (as indicated) was measured by ELISA. (b) SIGNR3-expressing RAW 264.7 macrophages were 
stimulated with 10 µg/ml ManLAM in the absence (dashed bars) or presence (black bars) of various concentrations of the Raf1 kinase inhibitor GW5074 
(0.1, 1, 10 µM). After 18 h of incubation, the secretion of IL-6 and TNF (as indicated) was measured by ELISA. (c) SIGNR3-expressing RAW 264.7 macro-
phages were stimulated with 10 µg/ml ManLAM or 0.5 µg/ml Pam3-Cys-SK4 lipopeptide in the absence (dashed bars) or presence (black bars for ManLAM, 
gray bars for lipopeptide) of various concentrations of the Syk inhibitor piceatannol (0.1, 1, and 10 µM for ManLAM, and 10 µM for lipopeptide). After 18 h  
of incubation, the secretion of IL-6 and TNF (as indicated) was measured by ELISA. (d) SIGNR3-expressing RAW 264.7 macrophages were stimulated with 
10 µg/ml ManLAM in the absence (dashed bars) or presence (black bars) of increasing concentrations of the Syk inhibitor R406 (0.5, 1, 2, and 5 µM).  
After 18 h of incubation, the secretion of IL-6 and TNF (as indicated) was measured by ELISA. (e) BMMs from C57BL/6 (Syk+/+) or from Syk/ animals 
were nucleofected with a control vector (Ctrl) or with a SIGNR3-expressing vector (SIGNR3). Cells were stimulated with 10 µg/ml ManLAM, and IL-6  
levels were determined by ELISA on cell supernatants after 18 h of incubation. For technical reasons, TNF secretion could not be assessed in these  
settings. In a–d, data are shown as in Fig. 5 a, and in a–e, the data shown are the means (± SD) of triplicate samples, reproduced in three (a–d) and two 
(e) independent experiments.JEM VOL. 206, September 28, 2009 
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liver endothelial cells (Geijtenbeek et al., 2002), with an ex-
pression pattern similar to that of L-SIGN in humans. The 
other mouse SIGNR lectins recognize different sugar moi-
eties, such as N-acetyl glucosamine for SIGNR2, or have no 
sugar-binding activity, as is the case for SIGNR4 (Powlesland 
et al., 2006). Thus, our findings support the hypothesis that 
human DC-SIGN and mouse SIGNR3 are functional ortho-
logues  that  are  duplicated  differently  within  and  between 
species during the course of evolution to fulfill different func-
tions (Bashirova et al., 2003).
We found that the early pulmonary resistance of SIGNR3-
deficient mice to M. tuberculosis was weaker than that of WT 
animals, although the infection was controlled in the longer 
term in KO animals. In contrast, SIGNR5- and SIGNR1-
KO animals were as resistant to the bacillus as WT control 
mice. The greater permissiveness to infection of SIGNR3-
deficient mice was consistent with the ability of the lectin to 
signal after binding its mycobacterial ligands, and to induce 
secretion of the inflammatory cytokines IL-6 and TNF in   
vitro in macrophages, and in vivo in the lungs of experimen-
tally infected animals, at least regarding TNF. These cytokines 
are essential for the control of mycobacterial infections (Flynn 
et al., 1995; Ladel et al., 1997; Saunders et al., 2000). Al-
though we could not evince a dramatic decrease in IL-6 se-
cretion in the lungs of SIGNR3-KO animals 21 d after 
infection (Fig. 6 g), the level of IL-6 transcript in these mice 
was  reduced  significantly  as  compared  with  WT  controls 
(unpublished data). Moreover our results obtained in vitro 
undoubtedly  show  that  SIGNR3  signaling  contributes  to   
IL-6 secretion. Although we can only speculate at this stage 
about the potential involvement of IL-6 in SIGNR3-medi-
ated protection against M. tuberculosis, our results for SIGNR3-
KO mice are reminiscent of those reported for IL-6 KO mice 
(Saunders et al., 2000). Indeed, in both mouse lines, early 
control of mycobacterial infection is impaired in the lungs, 
but not in other organs, such as the spleen, and the adaptive 
antimycobacterial immune response, longer term control of 
the infection, and survival of the infected animals were nor-
mal. The possible roles of IL-6 in the early control of M. tu-
berculosis infection have been discussed in detail by Saunders 
et al. (2000), and further work will be needed to firmly estab-
lish whether IL-6 plays a part in SIGNR3-mediated protec-
tion against the TB bacillus in vivo.
We showed that SIGNR3-mediated cytokine secretion 
required an intact tyrosine residue within the YxxL/I ITAM-
like motif in the cytoplasmic tail of the lectin, and that this 
process was associated with Syk and dependent on both the 
NF-B and Raf1–ERK pathways. These findings resemble 
Figure 9.  SIGNR3 collaborates with TLR2 to induce cytokine se-
cretion. (a) Rat6 fibroblasts were stably transfected with a control (Ctrl) 
or a SIGNR3-encoding (SIGNR3) vector. Cells were incubated with 19-kD 
protein for 1 h at 37°C, washed, and permeabilized, and the 19-kD anti-
gen was immunodetected with a Texas red–conjugated secondary anti-
body. Data are representative of three independent experiments. Bar,  
10 µm. (b) RAW 264.7–derived macrophages stably transfected with a 
SIGNR3-encoding (circles) or an empty control (squares) vector were left 
unstimulated (open symbols) or were stimulated (closed symbols) with  
0.3 µg/ml of 19–kD protein, and the secretion of IL-6 (left) and TNF (right) 
was measured by ELISA after 4, 12, and 24 h of incubation. *, P < 0.05; **, 
P < 0.01. (c) RAW 264.7–derived macrophages stably transfected with a 
SIGNR3-encoding (black bars) or an empty control (open bars) vector 
were incubated with an anti-TLR2 blocking antibody or left with no in-
hibitor (NI) for 1 h, after which cells were stimulated (Stim.) with 0.3 µg/ml 
of 19-kD protein or 0.5 µg/ml Pam3CSK4 lipopetide (Lp). We measured  
the secretion of IL-6 (left) and TNF (right) by ELISA after 18 h of incubation. 
(d) BMMs from C57BL/6 (Syk+/+) or from Syk/ animals were nucleo-
fected with a control vector (Ctrl) or with a SIGNR3-expressing vector  
(SIGNR3). Cells were stimulated with 0.3 µg/ml 19-kD protein, and IL-6 
levels were determined by ELISA in the cell supernatants after 18 h of 
incubation. Data shown as in Fig. 8 e. For technical reasons, TNF secretion 
could not be assessed in these settings. In b–d, the data shown are the 
means (± SD) of triplicate (b and c) and duplicate (d) samples, reproduced 
in at least two independent experiments.
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with TLR4, independently of Tyr31. The net effect of these 
multiple types of PRR stimulation on the immune response 
to M. tuberculosis remains unclear. The results obtained in this 
study with mice and the 19-kD protein, a mycobacterial 
TLR2 ligand also recognized by SIGNR3, suggest that 
SIGNR3 signaling synergizes with TLR2 for the production 
of protective inflammatory cytokines.
In summary, our results reveal, for the first time, the role 
of a C-type lectin, the DC-SIGN homologue SIGNR3, in 
innate resistance to M. tuberculosis in vivo. In addition to my-
cobacteria, DC-SIGN recognizes a plethora of viruses, bacte-
ria, and parasites. The identification of SIGNR3 as the most 
likely functional orthologue of DC-SIGN and the availability 
of a mouse line in which this receptor has been inactivated 
should facilitate further investigations of the role of this lectin 
in several infectious diseases.
MATERIALS AND METHODS
Binding experiments. Mycobacterial ManLAM, LM, and AraLAM were 
purified as previously described (Pitarque et al., 2005). The 19-kD lipopro-
tein was produced as previously described (Turner et al., 2004). The 38- and 
45-kD proteins were obtained from the Mycobacteria Research Laborato-
ries at Colorado State University (grant NIH HHSN266200400091c).   
Aliquots of mycobacterial antigens (50 ml) diluted to 2 ng/ml in a 1:1   
ethanol/water mixture were dried overnight in 96-well Immulon 4 plates 
(Thermo Fisher Scientific). Wells were blocked by incubation with 5% bo-
vine serum albumin in Tris-buffered saline for 2 h at 37°C and rinsed twice 
with binding buffer (150 mM NaCl, 25 mM Tris-Cl, pH 7.8, and 2 mM 
CaCl2). Tetrameric streptavidin complexes of biotin-tagged carbohydrate 
recognition domains from the mouse SIGNs were prepared as previously 
described (Powlesland et al., 2006), transferred to buffer containing sodium 
bicine, pH 8.5, in place of Tris buffer, reacted with radioiodinated Bolton-
Hunter reagent (GE Healthcare), and repurified by affinity chromatography. 
Binding experiments were performed by incubation for 2 h at room tem-
perature, with the labeled SIGNs diluted in binding buffer containing 0.5% 
bovine serum albumin. Wells were washed three times with binding buffer, 
and radioactivity was counted in a Wallac Wizard  counter. At the maxi-
mum concentrations tested, 0.4 µg/ml for SIGNR1, 12 µg/ml for SIGNR3, 
and 6 µg/ml for SIGNR5, only SIGNR3 began to show saturation. For 
comparisons, we calculated the fraction of the input radioactivity that bound 
from the linear portions of the binding curves.
Cell lines. Rat6 fibroblasts producing SIGNR1, SIGNR3, and SIGNR5 
were cultured as previously described (Powlesland et al., 2006). RAW 264.7 
macrophages (TIB71; American Type Culture Collection) were cultured in 
RPMI 1640 GlutaMAX (Invitrogen) supplemented with 10% FCS (Sigma-
Aldrich), 50 µM -mercaptoethanol (Invitrogen), 1 mM sodium pyruvate 
(Invitrogen), and 100 U/ml penicillin/streptomycin (Invitrogen).
Genetic  constructs  and  transfection. SIGNR3 cDNA was amplified 
from magnetic cell sorting–enriched preparations of CD11c+ lung cells with 
the following oligonucleotides: SIGNR3Fd, 5-CCACATGAGTGACTC-
CATGGAATCAAAG-3;  SIGNR3Rv,  5-CTATTTGGTGGTGCAT-
GATGAGGTTG-3 by PCR (Pfu; Stratagene). The cDNA was inserted 
into the pUNO expression vector (Invivogen) to generate pUNO-SIGNR3. 
The Y27S mutant was generated from pUNO-SIGNR3 by PCR-mediated 
mutagenesis, with the Phusion Site-Directed Mutagenesis kit (Finnzymes),   
used according to the manufacturer’s protocol, and the following oligonu-
cleotides: S3-Y/S-27-Fd, 5-GAGTGGCACCAGGTCTTCTGATATCA-
GCTC-3; S3-Y/S-27-Rv, 5-ATCAAACACTCTTCATCCTCTGGAA-
TGACC-3, generating pUNO-SIGNR3YS. RAW 264.7 cells were stably 
transfected  with  pUNO,  pUNO-SIGNR3,  and  pUNO-SIGNR3YS  by 
those for another myeloid C-type lectin, dectin-1 (Brown, 
2006), which mediates protection against fungal infections 
through the secretion of inflammatory cytokines and an oxi-
dative burst in a Syk- and CARD9/Bcl10-dependent man-
ner, via its cytoplasmic YxxL motif. Like SIGNR3, dectin 
can signal on its own, or in collaboration with TLR2 to 
modulate inflammatory responses. Several C-type lectins carry 
intracellular ITAM-like motifs, and Syk-mediated signaling 
may be a common feature of this PRR family.
Our results raise intriguing questions about the potential 
similarity of DC-SIGN and SIGNR3 functions in humans   
and mice, and about the overall beneficial or detrimental   
nature of the DC-SIGN–mediated immune response to   
M. tuberculosis in vivo for the host. Interestingly, SIGNR3 in 
infected mice and DC-SIGN in patients with TB have simi-
lar patterns of expression, with both lectins induced during 
the infection process in cells of myeloid origin (Fig. 5; Tailleux 
et al., 2005). In vitro, DC-SIGN may signal in a TLR- 
dependent (Geijtenbeek et al., 2003; Caparrós et al., 2006; 
Gringhuis et al., 2007) or -independent (Hodges et al., 2007) 
manner. In human DCs, DC-SIGN binding to ManLAM 
(Geijtenbeek et al., 2003) or agonist antibodies (Caparrós   
et al., 2006) has been reported to increase secretion of the 
antiinflammatory cytokine IL-10 if it coincides with TLR4 
stimulation by bacterial LPS. The intracellular Tyr31 residue 
in the cytoplasmic tail of DC-SIGN does not appear to be 
required for signaling in this case (Gringhuis et al., 2007). We 
observed no such increase in IL-10 secretion in SIGNR3-
expressing cells stimulated with both ManLAM and LPS, but 
it is likely that macrophages and DCs differ in this respect. 
However, the TLR-independent stimulation of DC-SIGN 
requires Tyr31 and leads to the induction of TNF (Hodges   
et al., 2007), consistent with our findings in mouse SIGNR3.
M. tuberculosis and Mycobacterium-derived compounds can 
interact with TLRs in vitro, leading to cell activation and cy-
tokine production (Jo, 2008). In vivo, TLR2 plays a key role 
in the production of TNF and IL-12, and TLR2-deficient 
mice have been reported to die earlier than WT controls after 
M. tuberculosis infection (Reiling et al., 2002), although these 
results were not confirmed in a more recent study of TLR2-
4-9 triple KO mice (Hölscher et al., 2008). In contrast, the 
role of TLR4 in TB remains unclear. M. tuberculosis-derived 
compounds can stimulate TLR4 (Means et al., 1999; Takeuchi 
et al., 2000) in vitro, but TLR4 does not appear to be in-
volved in antimycobacterial immunity in vivo, at least in 
mice (Reiling et al., 2002; Hölscher et al., 2008). Further in-
vestigations are required to determine whether DC-SIGN 
acts  together  with  TLR4  to  potentiate  IL-10  production 
during the natural course of TB in vivo in humans. Such a 
mechanism might result in immune evasion by the bacillus 
(Geijtenbeek et al., 2003). It might also make it possible to 
control inflammation and to limit host tissue damage, thereby 
contributing to host protection (Neyrolles et al., 2006). These 
results are compatible with a model in which, depending on 
the cell context, DC-SIGN may signal either as a single PRR 
along a pathway requiring the Tyr31 residue, or in association JEM VOL. 206, September 28, 2009 
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In some experiments, a blocking anti-TLR2 antibody (Clone T2.5; eBiosci-
ence) at a concentration of 50 µg/ml or the appropriate control isotype 
(mouse IgG1a; eBioscience) was used. LPS was used at a concentration   
of 100 ng/ml (Invivogen). In some experiments, cell signaling inhibitors 
were used at the concentrations indicated in the figure legends: U0126 
(ERK1/2 kinase), BAY117082 (NF-B), GW5074 (Raf1 kinase), piceatan-
nol (Syk), or R406 (Syk), which were all purchased from Calbiochem,   
except for R406 (provided by J. Schmitz, Rigel Pharmaceuticals, Inc., San 
Francisco,  CA),  and  diluted  in  dimethylsulfoxide  (Sigma-Aldrich).  After 
stimulation, cell culture, supernatants were harvested and TNF, IL-6, and 
IL-10 were detected by ELISA (OptEIA kits; BD) according to the kit   
manufacturer’s  instructions.  Nitric  oxide  production  was  measured  with 
Griess reagent (Invitrogen).
KO mice. The C57BL/6J mouse BAC clone RP23-12K14 (BACPAC 
Resources Center at Children’s Hospital Oakland Research Institute, Oak-
land,  CA),  based  on  a  sequence  from  the  Ensembl  database,  spans  the 
CD209a (SIGNR5), CD209b (SIGNR1), and CD209d (SIGNR3) genes. 
Using the BAC DNA as a template, we amplified homologous fragments by 
PCR. Two homologous fragments of the CD209a gene were inserted into 
the replacement KO vector pKO. Three homologous fragments of CD209b 
and CD209d were inserted separately into the conditional KO vector pKO-
3loxp. The three resulting targeted vectors were used to transfect Bruce 4 
embryonic stem (ES) cells, a C57BL/6 ES cell line. The homologous re-
combinant ES cell clones for each targeted gene were identified by South-
ern blotting. The selected ES clones carrying the homologous recombinant 
CD209a allele were injected into Albino B6 (The Jackson Laboratory) blas-
tocysts to generate CD209a chimeric mice. Homologous recombinant   
ES clones for CD209b and CD209d were further transfected with the 
pMC-Cre vector encoding the Cre recombinase and cultured with 2 µM 
ganciclovir  (Sigma-Aldrich).  The  ganciclovir-resistant  ES  cell  subclones 
bearing floxed alleles were stored in liquid nitrogen. ES clones with the 
delta allele were injected into Albino B6 blastocysts, to generate chimeric 
mice. Male chimeras were crossed with Albino B6 females. The resulting 
KO mice were backcrossed with C57BL/6 three times, and then inter-
crossed. The homozygous KO of CD209a, CD209b, and CD209d was 
confirmed by PCR, Southern blotting, and RT-PCR using the following 
primers: SIGNR3Fd, 5-TTGGTCCTGCAGCTGCTTTC-3; SIGNR3Rv, 
5-ACCGACATTGTTGGGCTCC-3; SIGNR5Fd, 5-AAATGGGGA-
AGAGGCAGCTTC-3; SIGNR5Rv, 5-CAGCCTTCAACTGGGTCAG-
TTC-3; -actinFd, 5-CCACACTGTGCCCATCTACGAG-3; -actinRv, 
5-CAGCACTGTGTTGGCATAGAGG-3.
Mouse infection. 6–8-week-old female C57BL/6J mice were purchased 
from CER Janvier. All mice were housed in pathogen-free conditions and 
treated according to institutional animal care protocol no. 20080318/9, ap-
proved by the Regional Ethics Committee of Midi-Pyrénées (France) for 
Animal Experimentation (authorization no. MP/01/36/06/08). For high-
dose  infections,  mice  were  anesthetized  with  a  cocktail  of  ketamine   
(100 mg/kg; Merial) and xylasine (15 mg/kg; Bayer). Mice were infected 
intranasally with 103 CFUs of M. tuberculosis in 20 ml of saline/0.01% Tween 80.   
Mice were killed by CO2 asphyxiation after various times. Lungs and spleens 
were harvested, homogenized, and plated on agar for colony counts.   
For low-dose infections, stock solutions of M. tuberculosis were diluted in 
sterile distilled water and pulmonary infection was achieved with a pediatric 
nebulization system. For mice infected with a dose of 100 CFU/lung, ani-
mals were exposed for 20 min to an aerosol generated by nebulizing 5 ml 
of a suspension containing 5 × 106 live bacteria/ml. Inoculum size was 
checked 24 h after infection by determining the bacterial load in the lungs   
of infected mice.
Intracellular cytokine staining and analysis of lymphocyte popula-
tions. For antigen-specific restimulation and flow cytometry analysis, single-
cell suspensions were prepared from the lungs of M. tuberculosis–infected mice 
at various time points. Mice were anesthetized and injected intraperitoneally 
nucleofection (Amaxa kit V), according to the manufacturer’s protocol (Cell 
Line Nucleofector kit V for RAW 264.7 cells). Stable transfectants were se-
lected on medium containing 40 µg/ml blasticidin (Invivogen), and were 
subsequently cultured in the presence of 10 µg/ml blasticidin. Transgene ex-
pression was assessed by qRT-PCR and immunostaining.
BMMs and nucleofection. BM cells from Syk/ mice (Turner et al., 
1995; provided by E. Schweighoffer and V. Tybulewicz, National Institute 
for Medical Research, London, England, UK) were prepapred by O. Joffre 
and C. Reis e Sousa. BM cells were flushed from the femurs and tibias of   
6–8-wk-old female C57BL/6 or Syk/ (Turner et al., 1995) mice, and re-
suspended in complete RPMI supplemented with 20 ng/ml recombinant 
M-CSF (Miltenyi Biotec). Macrophages were allowed to differentiate for   
7 d. BMM nucleofection was performed as described in the Mouse Macro-
phage Nucleofector kit (Lonza). In brief, after the differentiation of fresh   
or frozen BM-derived progenitors, cells were harvested in cell dissociation   
solution (Sigma-Aldrich) and washed twice in PBS. We then resuspended 1 
million cells in 100 µl Nucleofector Solution, to which we added 2 µg DNA 
(pUNO or pUNO::SIGNR3). Cell/DNA suspensions were then transfered 
into certified cuvettes, and the Y-001 nucleofection program was run. Nu-
cleofected cells were then resuspended in 500 µl of preequilibrated medium 
(RPMI 1640, 20% FCS, 100 µg/ml streptomycin, 100 U/ml penicillin,   
2 mM GlutaMAX), gently transfered into culture plates, and incubated in   
a humidified incubator at 37°C, in an atmosphere containing 5% CO2. After 
overnight incubation, the medium was changed and cells were used for 
analyses 24 h after nucleofection.
Mycobacteria. M. tuberculosis was cultured at 37°C in Middlebrook 7H9 
broth (Difco) supplemented with 10% ADC (5% bovine serum albumin frac-
tion V, 2% dextrose, and 0.003% beef catalase; Difco) and 0.05% Tween 80 
(Sigma-Aldrich), or in agar Middlebrook 7H11 broth (Difco) supplemented 
with OADC (0.05% oleic acid, ADC; Difco). DsRed-encoding M. tuberculosis 
was previously constructed for DsRed-BCG (Abadie et al., 2005).
Immunofluorescence and confocal microscopy. Cells were cultured 
on glass coverslips in 24-well plates (5 × 105 cells per well, in a volume of   
1 ml). Biotinylated ManLAM and LM were prepared as previously described 
(Pitarque et al., 2005). Rat6 cells were pulsed with biotinylated ManLAM 
(20 µg/ml), biotinylated LM (20 µg/ml), and the 19-kD protein (5 µg/ml) 
for 2 h at 37°C, and washed three times with saline. Cells were fixed in 4% 
paraformaldehyde in saline and incubated for 20 min in 1% BSA (Sigma- 
Aldrich), 0.1% FCS (Sigma-Aldrich), and 0.05% saponin (Sigma-Aldrich) in 
saline, to block nonspecific binding and to permeabilize the cells. Streptavidin-
Alexa Fluor 594 (Invitrogen) was used to detect Biot-LAM and Biot-LM. 
Primary rabbit serum against 19-kD (a gift from D. Young, National Insti-
tute for Medical Research, London, England, UK) and secondary goat   
anti–rabbit–Cy5 (GE Healthcare) were used to detect the 19-kD antigen. 
After labeling, coverslips were set in Fluoromount G (SouthernBiotech) on 
microscope slides. RAW 264.7 cells were fixed by incubation with Cytofix/
Cytoperm buffer (BD) for 20 min at room temperature, blocked by incuba-
tion for 20 min at room temperature in Perm/Wash buffer (BD), and incu-
bated for an additional 20 min at room temperature with ImageiT FX signal 
enhancer (Invitrogen). The cells were then incubated for 1 h at room tem-
perature with a primary rat IgG2a antibody directed against SIGNR3 (DS-
R3-1.1; Wethmar et al., 2006). Primary antibodies were detected with a goat 
anti–rat IgG-conjugated with Alexa Fluor 594 (Invitrogen). Slides were ob-
served by confocal microscopy, using an LSM510 apparatus (Carl Zeiss, Inc.). 
For flow cytometry analysis, the anti-SIGNR monoclonal antibody was de-
tected with an Alexa Fluor 647–conjugated goat anti–rat IgG antibody.
Cell stimulation and ELISA. Cells were stimulated at 37°C for various 
periods  of  time  with  10  µg/ml  ManLAM,  1  µg/ml  19-kD  protein,  or   
0.5 µg/ml PamCys3 lipopeptide (Invivogen) or M. tuberculosis at a multiplicity 
of infection of 5 bacteria/cell. For M. tuberculosis–infected cells, infection rate 
was quantified by flow cytometry using a DsRed-expressing bacterium.   2218 ROLE OF DC-SIGN IN TUBERCULOSIS | Tanne et al.
Statistical analyses. Data were analyzed using the Student’s t test, with 
Welch’s correction in cases of unequal variance, as assessed with the F test.
Online  supplemental  material.  Fig.  S1  depicts  comparative  genomic 
protein sequence and phylogeny analysis of human DC-SIGN, its paralogue 
L-SIGN, and their homologues in the mouse. Fig. S2–S4 illustrate the strat-
egy used to inactivate SIGNR1, SIGNR3, and SIGNR5, respectively, and 
show RT-PCR analysis of the KO and control animals. In Fig. S5, we 
show that SIGNR3 expression in macrophages does not influence nitric 
oxide production and does not enhance IL-10 secretion after TLR4 stimula-
tion by LPS. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090188/DC1.
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